Mylan (NSDQ:MYL) and Biocon announced today that a European Medicines Agency committee has recommended approval for its biosimilar insulin glargine, Semglee. The committee’s positive opinion brings the product one step closer to approval. The European Commission is slated to make a final decision in April. “We are pleased with CHMP’s decision to recommend approval of Mylan […]
Diabetes
Report: Advocacy groups urge Congress to fund diabetes research programs
Advocacy groups have reportedly warned Congress that if lawmakers don’t find permanent funding solutions for diabetes research programs, it could jeopardize important work being done around the country to help people living with diabetes. Politicians on Capitol Hill have provided funding that will support the Special Diabetes Program and the Special Diabetes Program for Indians through […]
Senseonics prices $50m notes offering, touts Q4 and full-year prelims
Senseonics (NYSE:SENS) announced today an underwritten offering of $50 million in 5.25% convertible senior notes due 2023, alongside a 30-day option for underwriters to buy up to an additional $7.5 million in notes to cover over-allotments. The notes, which mature on Feb. 1, 2023, will be convertible into shares of Senseonics’ common stock at approximately $3.40 […]
Global sales for Abbott’s diabetes biz jumps 33% in Q4
Worldwide sales for Abbott‘s (NYSE:ABT) diabetes business jumped 33% in the fourth quarter of 2017, the company reported, driven largely by its FreeStyle Libre continuous glucose monitoring system. The device is the only CGM system on the market that is calibrated at the factory and eliminates the need for people with diabetes to perform routine […]
Nemaura uplists shares to NASDAQ exchange
Nemaura Medical (OTC:NMRD) said today that shares of its common stock were approved to list on the NASDAQ exchange. The medtech company’s shares are slated to start trading on Jan. 25 under its existing symbol. Nemaura, which is developing a wireless continuous glucose monitor, finished its clinical trial program in Europe late last year and is […]
Glytec touts patient outcomes for diabetes management system
Four new studies were published in this month’s issue of the Journal of Diabetes Science and Technology touting patient outcomes linked to Glytec‘s eGlycemic diabetes management system, the company reported. In both inpatient and outpatient settings, the use of eGMS for insulin therapy management was safer and more effective than traditional standards of care. The studies reported […]
SFC Fluidics inks deal with JDRF to develop automated insulin delivery system
SFC Fluidics has inked a two-year deal with JDRF to develop an automated insulin delivery system that combines a continuous glucose monitor and an insulin delivery algorithm into a single disposable device. JDRF is slated to provide funding to the medical device company as part of its Artificial Pancreas Project, which aims to accelerate the […]
DarioHealth launches iPhone-compatible glucose meter in Australia
DarioHealth (NSDQ:DRIO) said today that the Lightning-enabled version of its blood glucose monitoring system is available in Australia. The device is designed to connect with the latest Apple products, including the iPhone 7, iPhone 8 and iPhone X. The product’s launch comes just one month after it won approval from Australian authorities. Israel-based DarioHealth reported that […]
Valeritas launches V-Go wearable insulin delivery device in Puerto Rico
Valeritas (NSDQ:VLRX) said today that its V-Go wearable insulin delivery system is available in Puerto Rico. The Bridgewater, N.J.-based company has partnered with Fusion Consulting group to promote V-Go to Puerto Rico-based endocrinologists and general practitioners with Type II diabetes patients. “We are excited to have partnered with Puerto Rico-based Fusion Consulting Group to help bring V-Go Wearable insulin […]
Report: Chinese bidders eye Johnson & Johnson’s diabetes biz
Chinese glucose monitor maker Sinocare (SZ:300298) and a sovereign wealth fund there are said to be in the hunt for the diabetes business Johnson & Johnson (NYSE:JNJ) is looking to unload. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later elected to […]